Cargando…

Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition

The recent development of mutant-selective inhibitors for the oncogenic KRAS(G12C) allele has generated considerable excitement. These inhibitors covalently engage the mutant C12 thiol located within the phosphoryl binding loop of RAS, locking the KRAS(G12C) protein in an inactive state. While clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huynh, Minh V., Parsonage, Derek, Forshaw, Tom E., Chirasani, Venkat R., Hobbs, G. Aaron, Wu, Hanzhi, Lee, Jingyun, Furdui, Cristina M., Poole, Leslie B., Campbell, Sharon L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352912/ https://www.ncbi.nlm.nih.gov/pubmed/35753348 http://dx.doi.org/10.1016/j.jbc.2022.102186

Ejemplares similares

Acyl-lipid desaturases and Vipp1 cooperate in cyanobacteria to produce novel omega-3 PUFA-containing glycolipids
por: Poole, Leslie B., et al.
Publicado: (2020)

Integrated Redox Proteomic Analysis Highlights New Mechanisms of Sensitivity to Silver Nanoparticles
por: Holmila, Reetta, et al.
Publicado: (2021)

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
por: Goebel, Lisa, et al.
Publicado: (2023)

Discovery of Spilanthol Endoperoxide as a Redox Natural Compound Active against Mammalian Prx3 and Chlamydia trachomatis Infection
por: Dushime, Rosine, et al.
Publicado: (2020)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Immune modulatory effects of oncogenic KRAS in cancer
por: Hamarsheh, Shaima’a, et al.
Publicado: (2020)

Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022)

Conquering oncogenic KRAS and its bypass mechanisms
por: Hou, Pingping, et al.
Publicado: (2022)

How cholesteryl ester transfer protein can also be a potential triglyceride transporter
por: Chirasani, Venkat R., et al.
Publicado: (2017)

Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
por: Sabnis, Amit J, et al.
Publicado: (2009)

Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
por: Collins, Meredith A., et al.
Publicado: (2012)

Oncogenic KRAS promotes malignant brain tumors in zebrafish
por: Ju, Bensheng, et al.
Publicado: (2015)

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu, Xinquan, et al.
Publicado: (2019)

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
por: Luo, Yongde, et al.
Publicado: (2021)

Covalent Degrader of the Oncogenic Transcription Factor β-Catenin
por: Gowans, Flor A., et al.
Publicado: (2023)

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
por: Stites, Edward C., et al.
Publicado: (2018)

Kras as a key oncogene and therapeutic target in pancreatic cancer
por: Collins, Meredith A., et al.
Publicado: (2014)

The proto-oncogene KRAS is targeted by miR-200c
por: Kopp, Florian, et al.
Publicado: (2013)

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype
por: Fu, Yong, et al.
Publicado: (2015)

KRAS insertion mutations are oncogenic and exhibit distinct functional properties
por: White, Yasmine, et al.
Publicado: (2016)

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer
por: Boutin, Adam T., et al.
Publicado: (2017)

Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer
por: Kamerkar, Sushrut, et al.
Publicado: (2017)

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
por: Tang, Daolin, et al.
Publicado: (2021)

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
por: Zhu, Gongmin, et al.
Publicado: (2021)

Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
por: Sunaga, Noriaki, et al.
Publicado: (2021)

Past and Future Strategies to Inhibit Membrane Localization of the KRAS Oncogene
por: Haidar, Malak, et al.
Publicado: (2021)

Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
por: Wang, Dali, et al.
Publicado: (2022)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
por: Salmón, Marina, et al.
Publicado: (2023)

CRISPR prime editing for unconstrained correction of oncogenic KRAS variants
por: Jang, Gayoung, et al.
Publicado: (2023)

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
por: Kim, Dongsung, et al.
Publicado: (2023)

Covalently Bonded Chitosan on Graphene Oxide via Redox Reaction
por: Bustos-Ramírez, Karina, et al.
Publicado: (2013)

Redox-triggered switching in three-dimensional covalent organic frameworks
por: Gao, Chao, et al.
Publicado: (2020)

Widespread occurrence of covalent lysine–cysteine redox switches in proteins
por: Rabe von Pappenheim, Fabian, et al.
Publicado: (2022)

Structural and functional interactions between the Ca(2+)-, ATP-, and caffeine-binding sites of skeletal muscle ryanodine receptor (RyR1)
por: Chirasani, Venkat R., et al.
Publicado: (2021)

The Oxidative State of Cysteine Thiol 144 Regulates the SIRT6 Glucose Homeostat
por: Long, David, et al.
Publicado: (2017)

Elucidation of the Molecular Basis and Cellular Functions of Vinculin-Actin Directional Catch Bonding
por: Chirasani, Venkat R., et al.
Publicado: (2023)

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
por: Sánchez-Muñoz, Alfonso, et al.
Publicado: (2010)

Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS
por: Stelniec-Klotz, Iwona, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e9bhfnd5d71hfpa4vgkjnr00cm